Physician profile
Ashley E Gemmell
NPI 1598058943
$3,427.68
in general payments reported to CMS, 2019-2025
37 companies · $263 in 2025
The $263 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $408 · 2020: $594 · 2021: $626 · 2022: $592 · 2023: $508 · 2024: $437 · 2025: $263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,208.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $562.80 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $337.35 | 2022-2025 | Freestyle Libre 3 |
| Amgen INC. | $318.62 | 2019-2025 | Evenity, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $312.39 | 2020-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $285.69 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amarin Pharma, INC. | $258.29 | 2019-2021 | |
| Abbvie INC. | $203.21 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $172.77 | 2020-2024 | Jardiance, Tradjenta, Synjardy |
| Merck Sharp & Dohme LLC | $101.93 | 2021-2023 | Verquvo, Belsomra, Steglatro |
| Janssen Pharmaceuticals, INC | $93.13 | 2019-2024 | Spravato, Xarelto |
| E.R. Squibb & Sons, L.L.C. | $66.60 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $64.51 | 2022 | |
| Novartis Pharmaceuticals Corporation | $57.88 | 2019-2022 | |
| Pfizer INC. | $56.72 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.20 | 2019-2023 | Xifaxan, Trulance |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $43.35 | 2019-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Medtronic, INC. | $42.85 | 2022 | |
| Sumitomo Pharma America, INC. | $38.08 | 2025 | Gemtesa, Myfembree |
| Dexcom, INC. | $35.72 | 2023-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $28.06 | 2022-2023 | |
| Eisai INC. | $27.16 | 2020-2021 | |
| Therapeuticsmd, INC. | $26.05 | 2019-2021 | |
| Ibsa Pharma INC. | $20.53 | 2022 | |
| Mannkind Corporation | $19.43 | 2021 | |
| Astellas Pharma US INC | $18.60 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $18.15 | 2020 | |
| Upsher-Smith Laboratories LLC | $17.81 | 2021 | |
| Boston Scientific Corporation | $17.49 | 2024 | Watchman Flx |
| Exact Sciences Corporation | $15.98 | 2023 | Cologuard Collection Kit |
| Genentech USA, INC. | $15.79 | 2021 | |
| Coloplast Corp | $15.61 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.55 | 2019 | |
| Mylan Specialty L.P. | $13.95 | 2021 | |
| Arbor Pharmaceuticals, INC. | $13.30 | 2019 | |
| Allergan, INC. | $13.19 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $12.21 | 2020 | |
| Scilex Pharmaceuticals INC. | $11.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Gemmell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.